Anticancer adjuvant composition containing RIP3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting RIP3 expression, and method for monitoring sensitivity of anticancer drug
Kim, You Sun,Koo, Gi Bang,Yun, Jung Ho,Kim, Woo Jung,Jo, Yu Na
申请号：
AU2014382143
公开号：
AU2014382143A1
申请日:
2014.11.25
申请国别(地区):
AU
年份:
2016
代理人:
摘要：
The present invention relates to an anticancer adjuvant pharmaceutical composition containing a receptor-interacting protein kinase-3 (RIP3) protein expression promoter or activator as an active ingredient. In addition, the present invention provides a method for enhancing cancer cell death, by administering, to cancer cells, a RIP3 protein expression promoter or activator and an anticancer drug in combination. Additionally, the present invention relates to: a method for screening for an anticancer adjuvant which enhances the sensitivity of an anticancer drug by promoting RIP3 expression； and a method for monitoring the sensitivity of an anticancer drug through whether RIP3 is expressed. Therefore, it is expected that pretreating a demethylating agent so as to induce RIP3 expression and then using a conventional chemotherapeutic agent in a patient lacking RIP3 expression could be an effective treatment strategy. In addition, it is expected that monitoring the sensitivity of an anticancer drug and screening for an anticancer adjuvant enhancing the sensitivity of an anticancer drug in cancer treatment could be an effective strategy.
